BMS Archive

Fungi · Scientific monograph

Cordyceps sinensis

Caterpillar Fungus

For educational and scientific research only. Not medical advice. Independently verify claims against the cited primary sources. Consult a qualified healthcare professional before using any plant or fungal preparation.

Research areas: Stress Response Research, Exercise & Physical Performance Research, Renal Mechanisms

Research overview

Historical use

Documented in Tibetan and Chinese medicine since at least the 15th century (Ben Cao Bei Yao, 1694). Traditionally collected at high altitude on the Tibetan Plateau, growing from the larvae of Hepialus moth caterpillars. Used to treat fatigue, respiratory weakness, sexual dysfunction, and as a general tonic for the elderly.

Modern research context

Studied for anti-fatigue, athletic performance enhancement, and immunomodulation [1][5]. A systematic review of RCTs demonstrated that Cordyceps sinensis mycelium used as adjuvant in lung cancer treatment was associated with improved clinical outcomes [3]. Bidirectional cardiac-regulatory effects have been described in clinical evaluations using network pharmacology [2]. A randomised controlled trial demonstrated efficacy for primary insomnia [4]. The expensive wild-harvested form is largely replaced by cultured mycelium (CS-4 strain) in research contexts [5].

Adverse effects

Mild GI upset (nausea, diarrhoea, dry mouth). Rare hypersensitivity reactions. Risk of hypoglycaemia with antidiabetic co-medication. Risk of bleeding with anticoagulants.

Contraindications

Anticoagulant therapy. Immunosuppressive therapy (cyclosporine — may potentiate nephrotoxicity or immunosuppression). Autoimmune diseases — use with caution. Not recommended pre-surgery.

Clinical and phytochemical data

Used part

Fruiting body (stromata) and mycelium; cultured mycelium (CS-4) used commercially

Primary active compounds

  • Cordycepin (3'-deoxyadenosine)

  • Adenosine

  • D-Mannitol (cordycepic acid)

  • Polysaccharides (CS-PS)

  • Beta-glucans

  • Ergosterol

Mechanism of action

Cordycepin inhibits mRNA polyadenylation, blocking RNA processing and thereby suppressing inflammatory cytokine production and tumour cell proliferation. Adenosine and cordycepin act on adenosine receptors (A1, A2A, A3), modulating cardiovascular and immune tone. Increases cellular ATP production via AMPK-mediated mitochondrial biogenesis. Anti-inflammatory via suppression of NF-κB and COX-2.

Pharmacokinetics

Absorption

No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Cordycepin is rapidly deaminated in plasma by adenosine deaminase to the less active 3'-deoxyinosine, significantly limiting systemic bioavailability. Plasma half-life is very short (minutes) unless adenosine deaminase is inhibited.

Distribution

No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Cordycepin distributes rapidly to tissues via equilibrative nucleoside transporters (ENTs) but is simultaneously deaminated in plasma. In animal models, intact cordycepin has been detected in liver, kidney, and spleen. Adenosine distributes widely to all tissues. No quantitative human tissue distribution studies are available for Cordyceps sinensis preparations.

Metabolism

No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Metabolic pathway data for cordycepin (primary active compound) available in Lee JB et al. (2019), Sci Rep (PMID 31673018): cordycepin is rapidly deaminated to 3'-deoxyinosine by adenosine deaminase; a nucleoside rescue pathway enables oral bioactivity despite this first-pass degradation. Rapid deamination by adenosine deaminase; hepatic xanthine oxidase pathway for purine catabolism.

Excretion

No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Renal excretion of deaminated metabolites.

Safety and interactions

Drug interactions

Serotonergic antidepressants (sertraline) — upper gastrointestinal bleeding documented in a retrospective chart review of adaptogen-antidepressant adverse events (PMID 37829299). No clinical interaction data are available for any other drug class co-administered with Cordyceps sinensis; interactions with anticoagulants, antidiabetic agents, and immunosuppressants remain theoretical only.

Toxicity

LD50 >3 g/kg (oral, mice) for cultured mycelium extract. Generally well-tolerated in clinical trials up to 3–4.5 g/day. No significant organ toxicity at standard doses.

Special precautions

Pregnancy

Insufficient clinical safety data. Traditionally used as a uterine stimulant in some contexts — avoid during pregnancy.

Lactation

No data on transfer to breast milk. Avoid during breastfeeding.

Hepatic impairment

No documented hepatotoxicity. Limited data in hepatic impairment; standard caution recommended.

Renal impairment

Paradoxically studied as a renoprotective agent in CKD. Some RCTs show benefit in reducing proteinuria; however, monitoring of renal function is advised and dose adjustment may be needed in severe impairment.

Sources and references

  1. [1] - Das G., "Cordyceps spp.: A Review on Its Immune-Stimulatory and Other Biological Potentials.", Front Pharmacol, 2020, PMID: 33628175
  2. [2] - Wang L., "Bidirectional regulatory effects of Cordyceps on arrhythmia: Clinical evaluations and network pharmacology.", Front Pharmacol, 2022, PMID: 36059969
  3. [3] - Wang C., "Adjuvant treatment with Cordyceps sinensis for lung cancer: A systematic review and meta-analysis of randomized controlled trials.", J Ethnopharmacol, 2024, PMID: 38484953
  4. [4] - Zhao S., "Effectiveness of fermentation broth of Cordyceps sinensis for primary insomnia: a randomized clinical trial with digital health tool.", Front Neurol, 2025, PMID: 40726627
  5. [5] - Łysakowska P., "Medicinal Mushrooms: Their Bioactive Components, Nutritional Value and Application in Functional Food Production-A Review.", Molecules, 2023, PMID: 37513265

Additional source links

Continue browsing